Canvuparatide (MBX 2109)

About MBX Biosciences

MBX Biosciences is focused on developing innovative peptide therapeutics for underserved endocrine and metabolic markets. Enabled by its proprietary PEP platform technology, the company is advancing a pipeline of candidates, with its lead program, canvuparatide, showing positive Phase 1 data and having completed a Phase 2 trial in hypoparathyroidism. The company's mission is to help patients live fuller, healthier lives by translating leading-edge peptide science into convenient, transformative medicines.

About MBX Biosciences

MBX Biosciences is focused on developing innovative peptide therapeutics for underserved endocrine and metabolic markets. Enabled by its proprietary PEP platform technology, the company is advancing a pipeline of candidates, with its lead program, canvuparatide, showing positive Phase 1 data and having completed a Phase 2 trial in hypoparathyroidism. The company's mission is to help patients live fuller, healthier lives by translating leading-edge peptide science into convenient, transformative medicines.

Therapeutic Areas